Cantor Fitzgerald Sticks to Their Hold Rating for Integra Lifesciences (IART)


In a report released today, Craig Bijou from Cantor Fitzgerald maintained a Hold rating on Integra Lifesciences (IART), with a price target of $57. The company’s shares closed on Friday at $54.87.

Bijou observed:

“We maintain our Neutral rating and 12-month price target of $50 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure.”

According to TipRanks.com, Bijou is a 4-star analyst with an average return of 5.1% and a 56.7% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Ra Medical Systems Inc, and Wright Medical Group.

Integra Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $60.40.

See today’s analyst top recommended stocks >>

The company has a one-year high of $67.50 and a one-year low of $42.14. Currently, Integra Lifesciences has an average volume of 489K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts